Today, we feature Northwest Biotherapeutics Inc (NASDAQ: NWBO), a clinical-stage biopharmaceutical company, as the top momentum gainer since it gained more than 17% touching its new 52-week highs during the last two consecutive trading days with significant numbers of shares exchanging hands. NWBO was among the top performers in the U.S. healthcare sector after gaining 16.9% during the last session and closed at its 52-week high of $9.18 while recording significant volumes of 8.4 million shares. During the last 5-trading sessions, NWBO surged 41.0% recording daily average volumes of 3.82 million shares, while the stock accumulated over 78% during the past one month with 30-day average volumes of 1.38 million shares. The stock skyrocketed after NWBO was granted a special permission to sell DCVax-L, an experimental brain cancer drug, through hospitals in Germany.
Company Description:
Northwest Biotherapeutics Inc (NASDAQ: NWBO) a biotechnology company, discovers, develops, and commercializes immunotherapy products. The company’s products generate and enhance immune system responses to treat cancer. The DCVax product candidate platform creates cancer immunotherapies.
1-Year Stock Chart:
Source: Bloomberg
